Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Watch

Neomorphic PIK3R1 Mutations Confer Sensitivity to MAPK Inhibitors

DOI: 10.1158/2159-8290.CD-RW2014-216 Published December 2014
  • Article
  • Info & Metrics
Loading
  • Major finding: Tumor-associated PIK3R1 truncation mutations promote activation of ERK and JNK signaling.

  • Mechanism: Nuclear PIK3R1R348* facilitates JNK protein complex assembly and induces prosurvival signaling.

  • Impact: Gain-of-function PIK3R1 mutations may represent a functional therapeutic target in cancer.

Mutations in PIK3R1, which encodes the p85α regulatory subunit of PI3K, are one of the most frequent genetic alterations observed in cancer. Interestingly, the most common recurrent PIK3R1 mutation, the PIK3R1R348* truncation mutation, does not activate the p110α catalytic PI3K subunit, as is observed with other PIK3R1 mutations, but instead has been shown to possess a gain-of-function activity. Neomorphic PI3KR1 mutations have broad implications for therapeutic treatment strategies, prompting Cheung and colleagues to study the functional consequences of PIK3R1R348* on cell survival, signaling, and drug sensitivity. A cytotoxicity screen using a collection of 145 compounds in cells expressing wild-type PIK3R1, PIK3R1R348*, or the PTEN-destabilizing mutant PIK3R1E160* revealed that distinct PIK3R1 mutations differentially sensitized cells to PI3K pathway inhibitors. Surprisingly, PIK3R1R348* expression rendered cells sensitive to MAPK pathway inhibitors, in particular MEK and JNK kinase inhibitors. In line with these results, an ovarian endometrioid cancer cell line harboring the neighboring PIK3R1L370fs truncation mutation also displayed sensitivity to MEK and JNK inhibition. Mechanistically, PIK3R1R348*-expressing and PIK3R1L370fs-expressing cells were characterized by elevated nuclear ERK1/2 and JNK phosphorylation, which was dependent on mutant PIK3R1 expression but occurred independently of canonical PI3K–AKT signaling. Dissection of these pathways revealed that PIK3R1R348* promoted ERK phosphorylation via BRAF-mediated activation of the MAPK kinases MKK1 (also known as MAP2K1) and MKK2 (MAP2K2), whereas PIK3R1R348*-driven activation of the JNK pathway was dependent on nuclear localization and phosphorylation of MLK3 (MAP3K11) and MKK7 (MAP2K7). PIK3R1R348* functioned as a scaffold to stabilize a multiprotein complex containing the small GTPases CDC42 and RAC1, MLK3, MKK7, JNK1, and JNK2 in the nucleus and activated JNK signaling to promote cell survival and invasion both in vitro and in vivo. Together, these findings highlight the functional contribution of neomorphic PIK3R1 mutations to cancer cell growth and provide insight into therapeutic strategies to target PIK3R1R348*-mutant tumors.

Cheung LW, Yu S, Zhang D, Li J, Ng PK, Panupinthu N, et al. Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK inhibitors. Cancer Cell 2014;26:479–94.

  • ©2014 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 4 (12)
December 2014
Volume 4, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Neomorphic PIK3R1 Mutations Confer Sensitivity to MAPK Inhibitors
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Neomorphic PIK3R1 Mutations Confer Sensitivity to MAPK Inhibitors
Cancer Discov December 1 2014 (4) (12) OF14; DOI: 10.1158/2159-8290.CD-RW2014-216

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Neomorphic PIK3R1 Mutations Confer Sensitivity to MAPK Inhibitors
Cancer Discov December 1 2014 (4) (12) OF14; DOI: 10.1158/2159-8290.CD-RW2014-216
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable
  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
Show more Research Watch

Mutations

  • Somatic Copy-Number Alterations Occur in the Tumor Microenvironment
  • Genomic Lesions Unrepaired at Mitosis Affect Clonal Evolution in Cancer
  • WWP1 Gain-of-Function Variants Inactivate PTEN to Raise Cancer Risk
Show more Mutations
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement